Gene therapy for AADC deficiency
The present invention is directed to compositions and methods for treating aromatic L -amino acid decarboxylase (AADC) deficiency. This invention includes a method of treating AADC deficiency in a pediatric subject, comprising the steps of: (a) providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, (b) stereotactically delivering the pharmaceutical formulation to at least one target site in the brain of the subject in a dose of an amount at least about 1.8×10 11 vg; wherein delivering the pharmaceutical formulation to the brain is optionally by frameless stereotaxy, and optionally wherein the dose is an amount of at least about 2.4×10 11 vg and in some embodiments wherein the pharmaceutical formulation comprises a rAAV2-hAADC vector concentration of about 5.7×10 11 vg/mL. This invention is also directed to methods for treating aromatic L -amino acid decarboxylase (AADC) deficiency, wherein the method optionally further comprises the step of administering a therapeutically effective dose of dopamine-antagonist to the subject such as risperidone. This invention is also directed to methods for treating aromatic L -amino acid decarboxylase (AADC) deficiency, wherein the method optionally comprises providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, and empty capsids.
1. A method of treating aromatic L-amino acid decarboxylase (AADC) deficiency in a pediatric subject, the method comprising:
(a) providing a pharmaceutical formulation comprising an rAAV2-hAADC vector comprising (i) a wild type AAV2 capsid, and (ii) a recombinant DNA dopa decarboxylase (DDC) gene insert comprising a nucleic acid sequence encoding hAADC; and
(b) delivering the pharmaceutical formulation to at least one target site in the brain of the subject in a dose of an amount of at least 1.8×10 11 vg; wherein the pharmaceutical formulation further comprises empty AAV2 capsids at a percentage from about 50% cp/cp up to about 90% cp/cp, wherein the pharmaceutical formulation is delivered by stereotaxy.
2. The method of claim 1 , wherein the dose is about 1.8×10 11 vg.
3. The method of claim 1 , wherein the percentage of empty AAV2 capsids is at least about 75% cp/cp.
4. The method of claim 1 , wherein the pediatric subject is less than about three years in age.
5. The method of claim 1 , wherein the pediatric subject is about three or more years in age.
6. The method of claim 1 , wherein the pediatric subject is human.
7. The method of claim 1 , wherein the nucleic acid sequence encoding hAADC is an unmodified DDC cDNA.
8. The method of claim 1 , wherein the recombinant DNA DDC gene insert comprises from 5′ to 3′ (i) a first inverted terminal repeat (ITR), (ii) a cytomegalovirus (CMV) immediate early promoter (IEP), (iii) a human β-globin partial intron2/exon 3, (iv) the nucleic acid sequence encoding hAADC, (v) a SV40 poly A tail, and (vi) a second ITR.
9. The method of claim 1 , wherein the pharmaceutical formulation comprises the rAAV2-hAADC vector at a concentration of about 5.7×10 11 vg/mL.
10. The method of claim 1 , wherein the pharmaceutical formulation is delivered by frameless stereotaxy.
11. The method of claim 1 , wherein the pharmaceutical formulation is delivered at a rate of about 3 μL/min.
12. The method of claim 1 , wherein the pharmaceutical formulation is delivered to the at least one target site at a dose volume of about 80 μL per target site.
13. The method of claim 1 , wherein the pharmaceutical formulation is delivered to a putamen of the brain.
14. The method of claim 1 , wherein the pharmaceutical formulation is delivered bilaterally to each putamen.
15. The method of claim 1 , wherein the pharmaceutical formulation is delivered bilaterally to each putamen at target sites about 1 mm to about 10 mm apart.